Type2 diabetes mellitus
Conditions
Interventions
SGLT2i, dapagliflozin 5mg, is administrated once a daily after breakfast during 6-months
3-months after the start of SGLT2i, low dose sulfonylurea, glimeprid 0.5mg, or DPP-4i, linagliptin 5mg, is adde
Sponsors
Chiba Central Medical Center, Diabetes Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with Type2 DM who have been treated on life-style intervension alone and on life-style intervension plus metformin and whose HbA1c have not been controlled under 7.5%
Exclusion criteria
Exclusion criteria: 1. Malignancy 2. Renal dysfunction(eGFR<60ml/min) 3. Liver dysfunction(AST>100U/l and/or ALT100>100U/l), except of fatty liver or non-alcoholic steatohepatitis 4. Pregnancy 5. Lactation 6. History of treatment for ischemic heart disease or other severe cardiovascular disease 7. Administration of any drugs affecting plasma glucose concentration
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The alternations in glucose and insulin responses after the intravenous glucose load, HbA1c level and fasting glucagon concentration 3 months after administration of SGLT2i and then 3 months after addition of SU or DPP-4i to SGLT2i. | — |
Countries
Japan
Contacts
Public ContactAtsuya Horie
Chiba Central Medical Center Diabetes Center
Outcome results
None listed